These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2006-003580-31 A Study of the Efficacy of MORAb-003 in Subjects with Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse 2010-02-02 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-007633-39 A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study Of The Efficacy Of MORAb-009 In Combination With Gemcitabine In Patients With Advanced Pancreatic Cancer 2009-12-16 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-005448-18 An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma 2013-12-31 bad-data
Completed, but no date, and reported results Terminated 2008-005449-43 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory Rel... bad-data
Completed, but no date, and reported results Terminated 2009-015825-36 An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects with Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse bad-data
Listed as ongoing, but also has a completion date and reported results 2010-022229-13 A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in combination with Carboplatin and Paclitaxel or Docetaxel Followed by Pemetrexed in Chemotherapy na... 2013-10-31 bad-data
Ongoing 2011-001282-40 A Study of the Efficacy and PK/PD Relationship of Monotherapy MORAb-004 in Subjects with Metastatic Melanoma not-yet-due
Not reported 2012-001399-12 A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcoma 2016-02-29 due-trials
Ongoing 2014-003812-36 A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylate... not-yet-due
Ongoing 2014-004489-85 A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma not-yet-due